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Objectives: The aim of this study was to determine NT-proBNP serum levels in patients with untreated SLE, thus ruling out any potential effect of SLE therapy: to analyze any possible correlation between NT-proBNP values and traditional risk factors (TRF), inflammatory markers and myocardial function parameters. Methods: The study included 28 pts (82% females, aged 28,5 [25,0-32,0] years (median [interquartile range 25%>75%]) with untreated SLE (ACR criteria, 1997) and 27 healthy controls (89% females, age 30,0 [23,0-49,0] years). None of SLE pts was treated either with prednisone or cytotoxic drugs at the moment of inclusion, 5 (18%) pts received hydroxychloroquine 200 mg/day. SLE-related factors, including disease duration, clinical features, SLE Disease Activity Index (SLEDAI 2K) and Systemic Lupus International Collaborating Clinics damage index (SLICC/DI) were evaluated in parallel with relevant laboratory findings (blood and urine tests, CRP, IL-6, INF-α, immunoglobulins G, A and M, C3 and C4 complement fragments and others), autoantibodies (ANA, antiDNA, ENA-SSA, -SSB, -Sm, -RNP-70, aPL), echocardiography was performed using standard techniques. Serum levels of NT-proBNP (pg/ml) were measured using electrochemiluminescence method Elecsys proBNP II (Roche Diagnostics, Switzerland). Normal NT-proBNP levels should vary within ≤125,0 pg/mL. Results: Mean SLE duration was 21,0 [5,0-60,0] months, SLEDAI 2K score -11 [8] [9] , SLICC/DI score -0 [0-0]. SLE pts had higher levels of NT-proBNP vs control (160,7 [88,6-335,4] vs 55,2 [36,6-70,3 ] pg/ml, p<0,001). Elevated levels of NTproBNP (>125,0 pg/ml) was detected in 18 (64%) SLE pts. In SLE pts NT-proBNP serum levels showed positive correlation with creatinine (r=0,480, p<0,01), uric acid (r=0,427, p<0,05) , ACL IgG (r=0, 710, p<0, 001), antiDNA (r=0, 395, p<0, 05) , ANA levels (r=0, 256, p<0, 05) , left ventricle (LV) end-systolic dimension (r=0,442, p<0,05) , mean pulmonary artery pressure (r=0,486, p<0,05) ; and negative correlation with hemoglobin level (r=-0,493, p<0,01) , C4 complement component (r=-0,475, p<0,05) , glomerular filtration rate (r=-0,558, p<0,01) and LV ejection fraction (r=-0,505, p<0,01); left ventricular diastolic dysfunction (DDLV) was only in pts with NT-proBNP levels >125,0 pg/ml. Mean NT-proBNP concentration in verified DDLV cases (n=5 (18%)) considerably exceeded normal values, reaching up to 799,2 [276,6-1777,0] pg/ml. Conclusions: Untreated SLE patients without a history of myocardial infarction, coronary procedure or any evidence of heart failure demonstrated higher NTproBNP concentration as compared to healthy controls (p<0,001). NT-proBNP levels showed correlation with numerous SLE markers (ACL IgG, ANA, antiDNA, C4 fragment of complement), kidney function (creatinine, uric acid, glomerular filtration rate) and myocardial function (end-systolic dimension of the LV, mean pulmonary artery pressure, LV ejection fraction). No correlation was documented between NT-proBNP concentration and TRF or inflammatory markers (CRP, IL-6, INF-α). All abovementioned data suggest presumable SLE-associated autoimmune damage of cardiomyocytes and/or mediated decrease of myocardial function caused by kidney disease. Background: Prevalence of neurological involvements (NI) in primary Sjögren Syndrome (pSS) varies from 10 to 60% and depends on whether they are screened systematically or only when they are symptomatic. Objectives: The aim of the study was to describe the prevalence, clinical patterns and treatment of NI in pSS. Methods: We performed a retrospective study of patients with pSS (AmericanEuropean Consensus Group criteria) and followed in an internal medical department over a period of 15 years. Patients with NI were enrolled after excluding other potential causes. We did investigate neurologic systems only when patients present with symptoms. Results: Primary Sjögren Syndrome was diagnosed in 155 patients, 41 had neurological manifestations (26.4%). They were 5 male and 36 female. The mean age at disease onset was 49 +/-13 years. The average delay from NI onset to pSS diagnosis was four months for peripheral nervous system (PNS) and 12 months for central nervous system (CNS). NI revealed the disease in 14 cases (34%). CNS and PNS involvements were respectively found in 27 and 19 cases (six patients had both PNS and CNS). In patients with CNS disorders, headache was the most frequent symptom (n=11). Pyramidal syndrome was found in 9 cases and cerebellar syndrome in one patient. Aseptic meningitis was noted in two cases. Brain MRI was performed in 22 cases and showed abnormalities in 82% of cases. T2 and flair weighted hyperintensities were periventricular (n=11), subcortical (n=5), frontal (n=3) and parietal (n=2). Myelitis was found in one patient. Patients with PNS showed paresthesia (92%), motor deficit (22%) and decreased tendon reflex (18%). Sensory-motor neuropathy was described in 4 cases, pure sensory neuropathy in 6 cases (including one case of small fiber neuropathy) and motor neuropathy in one patient. Mononeuropathy multiplex was found in 4 cases and polyradiculoneuritis in one patient. Neuromuscular biopsy was performed in five patients and showed vasculitis in two cases. Trigeminal nerve and cochlear nerve were respectively involved in four and one patients. Antinuclear antibodies, anti-SSA and anti-SSB antibodies were respectively positive in 71%, 50% and 28% of cases. NI were treated with corticosteroids and immunosuppressive therapy in respectively 56% and 41% of cases. Outcome was good in 48% of the patients. Comparison of clinical and biological features in patients with and without NI showed no significant differences, only fatigue was significantly associated to NI (45.5% vs 12.9%; p=0.005). Conclusions: In our series, NI prevalence was similar to other groups. CNS involvements were more frequent than PNS manifestations whereas in other ethnic groups they are less frequent. Background: Fever is one of the main symptoms leading to the admission of patients with systemic lupus erythematosus (SLE) and its causes are usually complicated. Objectives: To explore the prevalence and clinical characteristics of fever in Chinese SLE patients at the time of their first admission and to find out whether fever is related to a poor prognosis. Methods: A follow-up study aimed to delineate SLE prognosis had been conducted by our Lupus Collaborative Group under the supervisor of Jiangsu Rheumatology Association to collect the data of patients who had ever recorded first admissions during the 1999-2009 decade (1). Among which, those with admission temperature documented were extracted for the assessment of potential factors associated with fever. The independency of various clinical features linked to fever was established by binary logistic regression analysis, and the relation between fever and patient's survival was determined by Cox regression analysis. Results: Totally 1,348 patients were enrolled, in which 1,049 (77.8%) had normal temperature, 221 (16.4%) had low and moderate fever and 78 (5.8%) had high fever at the time of their first hospitalization. Compared with those having normal temperature, fever patients were more likely to have short disease duration (RR 0.74), concurrent infection (RR 3.29) and gastrointestinal (RR 1.57) as well as hematological involvements (RR 1.56). High C reactive protein level (RR 2.08) and positive anti-Sm antibody (RR1.55) were the two laboratory factors related to fever at admission. However, age, gender, SLEDAI score or erythrocyte sedimentation rate was not independently associated with fever in this cohort. Cox regression analysis showed that there was no correlation between fever and overall deaths (Figure 1 ) as well as infection induced deaths.
Conclusions: Both infection and lupus itself (especially gastrointestinal and hematological involvements) contribute to fever in SLE patients. Although the presence of fever increases the complexity of disease treatment, it does not constitute a risk factor for patient's long-term outcome. 
